Do analysts recommend GRI or CYCN?

GRI Bio currently has a consensus target price of $21.00, suggesting a potential upside of 924.39%. Given GRI Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe GRI Bio is more favorable than Cyclerion Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CTXR or GRI?

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Pharmaceuticals N/A N/A -$37.43M -$1.67 N/A GRI Bio N/A N/A -$11.96M -$38.37 N/A

Is CTXR or GRI more profitable?

Citius Pharmaceuticals' return on equity of -59.57% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -59.57% -34.47% GRI Bio N/A -134.03% -106.83%

Which has better earnings and valuation, GRI or MBRX?

Moleculin Biotech is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$38.37 N/A Moleculin Biotech N/A N/A -$33.56M -$7.13 N/A

Is GRI or MBRX more profitable?

GRI Bio's return on equity of -134.03% beat Moleculin Biotech's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -134.03% -106.83% Moleculin Biotech N/A -143.51% -24.53%

Which has better valuation & earnings, GRI or PSTV?

Plus Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$38.37 N/A Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A

Is GRI or PSTV more profitable?

GRI Bio has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. GRI Bio's return on equity of -134.03% beat Plus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -134.03% -106.83% Plus Therapeutics -230.24% -198.48% -73.13%

Is GRI or DARE more profitable?

GRI Bio has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. GRI Bio's return on equity of -134.03% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -134.03% -106.83% Dare Bioscience -803.80% -748.30% -38.75%

GRI Bio (GRI) Competitors

$2.05 -0.04 (-1.91%)

Closing price 04:00 PM Eastern

Extended Trading

$2.01 -0.04 (-1.95%)

As of 04:23 PM Eastern

Compare

GRI vs. CYCN, CTXR, MBRX, PSTV, and DARE

Should you buy GRI Bio stock or one of its competitors? GRI Bio's main competitors and comparable companies include Cyclerion Therapeutics (CYCN), Citius Pharmaceuticals (CTXR), Moleculin Biotech (MBRX), Plus Therapeutics (PSTV), and Dare Bioscience (DARE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GRI Bio compare to Cyclerion Therapeutics?

GRI Bio (NASDAQ:GRI) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

GRI Bio has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cyclerion Therapeutics has higher revenue and earnings than GRI Bio. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
Cyclerion Therapeutics	$2.07M	7.89	-$3.53M	-$1.66	N/A

GRI Bio has a beta of -1.24, meaning that its share price is 224% less volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

In the previous week, GRI Bio and GRI Bio both had 1 articles in the media. GRI Bio's average media sentiment score of 1.82 beat Cyclerion Therapeutics' score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company	Overall Sentiment
GRI Bio	Very Positive
Cyclerion Therapeutics	Neutral

GRI Bio currently has a consensus target price of $21.00, suggesting a potential upside of 924.39%. Given GRI Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe GRI Bio is more favorable than Cyclerion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cyclerion Therapeutics beats GRI Bio on 8 of the 14 factors compared between the two stocks.

How does GRI Bio compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$1.67	N/A
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A

In the previous week, Citius Pharmaceuticals had 2 more articles in the media than GRI Bio. MarketBeat recorded 3 mentions for Citius Pharmaceuticals and 1 mentions for GRI Bio. GRI Bio's average media sentiment score of 1.82 beat Citius Pharmaceuticals' score of 0.61 indicating that GRI Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Positive
GRI Bio	Very Positive

Citius Pharmaceuticals' return on equity of -59.57% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-59.57%	-34.47%
GRI Bio	N/A	-134.03%	-106.83%

Citius Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, GRI Bio has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market.

Citius Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 764.15%. GRI Bio has a consensus target price of $21.00, suggesting a potential upside of 924.39%. Given GRI Bio's higher probable upside, analysts clearly believe GRI Bio is more favorable than Citius Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 5.0% of Citius Pharmaceuticals shares are owned by insiders. Comparatively, 8.7% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Citius Pharmaceuticals beats GRI Bio on 7 of the 13 factors compared between the two stocks.

How does GRI Bio compare to Moleculin Biotech?

GRI Bio (NASDAQ:GRI) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GRI Bio's return on equity of -134.03% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
Moleculin Biotech	N/A	-143.51%	-24.53%

GRI Bio has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Moleculin Biotech is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

In the previous week, Moleculin Biotech had 4 more articles in the media than GRI Bio. MarketBeat recorded 5 mentions for Moleculin Biotech and 1 mentions for GRI Bio. GRI Bio's average media sentiment score of 1.82 beat Moleculin Biotech's score of 0.16 indicating that GRI Bio is being referred to more favorably in the media.

Company	Overall Sentiment
GRI Bio	Very Positive
Moleculin Biotech	Neutral

GRI Bio presently has a consensus price target of $21.00, indicating a potential upside of 924.39%. Moleculin Biotech has a consensus price target of $3.00, indicating a potential upside of 398.67%. Given GRI Bio's higher possible upside, equities analysts plainly believe GRI Bio is more favorable than Moleculin Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

GRI Bio beats Moleculin Biotech on 6 of the 11 factors compared between the two stocks.

How does GRI Bio compare to Plus Therapeutics?

GRI Bio (NASDAQ:GRI) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Plus Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

GRI Bio has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

GRI Bio presently has a consensus price target of $21.00, suggesting a potential upside of 924.39%. Plus Therapeutics has a consensus price target of $51.75, suggesting a potential upside of 2,667.38%. Given Plus Therapeutics' higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than GRI Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, GRI Bio and GRI Bio both had 1 articles in the media. GRI Bio's average media sentiment score of 1.82 beat Plus Therapeutics' score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.

Company	Overall Sentiment
GRI Bio	Very Positive
Plus Therapeutics	Neutral

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GRI Bio has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. GRI Bio's return on equity of -134.03% beat Plus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Summary

GRI Bio beats Plus Therapeutics on 7 of the 12 factors compared between the two stocks.

How does GRI Bio compare to Dare Bioscience?

GRI Bio (NASDAQ:GRI) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

GRI Bio presently has a consensus price target of $21.00, suggesting a potential upside of 924.39%. Dare Bioscience has a consensus price target of $6.50, suggesting a potential upside of 738.17%. Given GRI Bio's higher probable upside, research analysts clearly believe GRI Bio is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

GRI Bio has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. GRI Bio's return on equity of -134.03% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-134.03%	-106.83%
Dare Bioscience	-803.80%	-748.30%	-38.75%

GRI Bio has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

In the previous week, GRI Bio and GRI Bio both had 1 articles in the media. GRI Bio's average media sentiment score of 1.82 beat Dare Bioscience's score of 1.79 indicating that GRI Bio is being referred to more favorably in the media.

Company	Overall Sentiment
GRI Bio	Very Positive
Dare Bioscience	Very Positive

GRI Bio has higher earnings, but lower revenue than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$38.37	N/A
Dare Bioscience	$1.03M	14.81	-$13.40M	-$0.70	N/A

Summary

GRI Bio beats Dare Bioscience on 8 of the 12 factors compared between the two stocks.

Get GRI Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRI vs. The Competition

Export

Metric	GRI Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.49M	$12.50B	$7.27B	$13.17B
Dividend Yield	N/A	2.62%	2.52%	12.57%
P/E Ratio	-0.05	792.35	274.71	25.79
Price / Sales	N/A	1,000.83	681.64	110.71
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	0.49	10.62	10.46	6.31
Net Income	-$11.96M	$2.81B	$3.49B	$359.77M
7 Day Performance	6.22%	-1.05%	-1.23%	-0.12%
1 Month Performance	4.59%	-2.93%	-4.48%	-4.01%
1 Year Performance	-96.21%	2.65%	16.46%	6.19%

GRI Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRI GRI Bio	3.3886 of 5 stars	$2.05 -1.9%	$21.00 +924.4%	-96.5%	$4.49M	N/A	N/A	5	Positive News
CYCN Cyclerion Therapeutics	0.6603 of 5 stars	$3.49 +3.9%	N/A	-84.7%	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
CTXR Citius Pharmaceuticals	2.4497 of 5 stars	$0.56 -2.3%	$5.00 +792.7%	-52.1%	$15.73M	N/A	N/A	20
MBRX Moleculin Biotech	3.1057 of 5 stars	$0.75 -3.0%	$3.00 +299.1%	-94.7%	$15.10M	N/A	N/A	20	Short Interest Increase Gap Down
PSTV Plus Therapeutics	1.2992 of 5 stars	$2.17 -6.7%	$51.75 +2,284.8%	-80.7%	$14.94M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRI) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRI Bio (GRI) Competitors

GRI vs. CYCN, CTXR, MBRX, PSTV, and DARE

How does GRI Bio compare to Cyclerion Therapeutics?

Summary

How does GRI Bio compare to Citius Pharmaceuticals?

Summary

How does GRI Bio compare to Moleculin Biotech?

Summary

How does GRI Bio compare to Plus Therapeutics?

Summary

How does GRI Bio compare to Dare Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRI Bio (GRI) Competitors

GRI vs. CYCN, CTXR, MBRX, PSTV, and DARE

How does GRI Bio compare to Cyclerion Therapeutics?

Is GRI or CYCN more profitable?

Do institutionals and insiders hold more shares of GRI or CYCN?

Which has preferable valuation and earnings, GRI or CYCN?

Which has more volatility & risk, GRI or CYCN?

Does the media refer more to GRI or CYCN?

Do analysts recommend GRI or CYCN?

Summary

How does GRI Bio compare to Citius Pharmaceuticals?

Which has better earnings and valuation, CTXR or GRI?

Does the media refer more to CTXR or GRI?

Is CTXR or GRI more profitable?

Which has more volatility and risk, CTXR or GRI?

Do analysts recommend CTXR or GRI?

Do insiders & institutionals have more ownership in CTXR or GRI?

Summary

How does GRI Bio compare to Moleculin Biotech?

Do insiders and institutionals believe in GRI or MBRX?

Is GRI or MBRX more profitable?

Which has more risk and volatility, GRI or MBRX?

Which has better earnings and valuation, GRI or MBRX?

Does the media favor GRI or MBRX?

Do analysts recommend GRI or MBRX?

Summary

How does GRI Bio compare to Plus Therapeutics?

Which has better valuation & earnings, GRI or PSTV?

Which has more volatility & risk, GRI or PSTV?

Do analysts recommend GRI or PSTV?

Does the media prefer GRI or PSTV?

Do insiders & institutionals have more ownership in GRI or PSTV?

Is GRI or PSTV more profitable?

Summary

How does GRI Bio compare to Dare Bioscience?

Do analysts rate GRI or DARE?

Do institutionals & insiders have more ownership in GRI or DARE?

Is GRI or DARE more profitable?

Which has more volatility & risk, GRI or DARE?

Does the media favor GRI or DARE?

Which has stronger earnings and valuation, GRI or DARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools